Business
Champions Oncology Announces the Formation of Corellia AI, a Wholly Owned Biotech that Leverages Unique AI-Enabled Workflows for Novel Therapeutic Development
HACKENSACK, NJ / ACCESSWIRE / April 17, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled research organization that is
About this update from Champions Oncology, Inc.
[{"type":"text","content":"HACKENSACK, NJ / ACCESSWIRE / April 17, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled research organization that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic (PPMO) integration, announced the launch of its therapeutic discovery and development platform into a wholly owned subsidiary named Corellia AI (Corellia). Corellia launches out of Champions Oncology with a team of world class scientists advancing a robust pipeline of therapeutic programs and a unique discovery and development platform. The company will continue to leverage Champions' superior PDX Molecular Atlas and its living bank of PDX models as central tools in its proprietary target and therapeutic discovery platform. The comprehensive discovery platform established by Corellia boasts AI-mediated technology that yields an extremely deep and continuously growing pool of novel therapeutic targets, and AI-guided technology for the discovery of novel therapeutic chemistry. Corellia's objective is to develop innovative first-in-class Antibody Drug Conjugates (ADCs) for patients with high unmet needs, at a pace and efficiency never achieved before.Ronnie Morris, MD, President and CEO of Champions Oncology, who will also serve as Executive Chairman of Corellia AI said \"I'm thrilled about the formation of Corellia. The therapeutic discovery initiative at Champions has been an exciting endeavor which utilizes our deep data. This team has been very effective at identifying interesting novel targets and has rapidly built therapeutic programs around these targets. So, launching this into a wholly owned subsidiary has been a natural next step, and will allow us to facilitate future growth. I look forward to seeing the continued growth and success of this organization as we enter this next phase.\"\"The evolution of Champions' therapeutic discovery and development initiative into an early-stage biotech has been a thrilling experience,\" said Michael Ritchie, PhD, M.B.A, Chief Commercial Officer at Champions Oncology who will serve as Chief Executive Officer of Corellia AI. \"The discovery platform built by the Corellia team is truly unique, and it has enabled the development of an exciting set of early therapeutic programs. We have plans to aggressively move these programs into the clinic and leverage our...